For Medical Professionals

Through TauRx’s technology platform, the company is continuing to discover, assess and develop new compounds and biologics with therapeutic and diagnostic promise for neurodegenerative diseases caused by protein aggregation.

The company’s lead proprietary compound has recently completed three Phase 3 clinical trials to evaluate its safety and efficacy in the treatment of Alzheimer’s disease and behavioural-variant frontotemporal dementia. This compound is now being evaluated in a new clinical trial named LUCIDITY.